Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
Inspire Medical Systems director reports stock compensation. Director Georgia Melenikiotou reported acquiring 180 shares of Inspire Medical Systems common stock on 01/15/2026 at a price of $96.47 per share. These shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, meaning board fees were paid in stock instead of cash. Following this transaction, Melenikiotou beneficially owned 4,166 shares of Inspire Medical Systems common stock, held directly.
Inspire Medical Systems director Shelley G. Broader reported receiving company stock as part of her board compensation. On 01/15/2026, she acquired 200 shares of Inspire Medical Systems common stock at $96.47 per share, taken in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this grant, she beneficially owned 4,567 common shares directly.
Inspire Medical Systems director reports stock award
Director Casey M. Tansey reported receiving 181 shares of Inspire Medical Systems common stock on January 15, 2026, coded as an acquisition. The shares were valued at $96.47 each and were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this award, Tansey holds 22,416 common shares directly.
In addition, two family trusts each hold 500 Inspire Medical Systems common shares, identified as the Kimberly Tansey Irrevocable Trust and the Kylie Tansey Irrevocable Trust, reported as indirect beneficial ownership.
Inspire Medical Systems, Inc. reported that it has issued a press release with certain preliminary, unaudited financial results for the quarter and full year ended December 31, 2025, which are still subject to closing procedures and internal control review.
The company’s board appointed Matthew J. Osberg as Chief Financial Officer, to become effective the day after Inspire files its Annual Report on Form 10-K for 2025. He will also serve as principal financial officer and principal accounting officer. His employment agreement provides a $650,000 annual base salary, a target annual cash bonus equal to 70% of base salary, a $600,000 cash sign-on bonus, and long-term equity incentives in the form of performance stock units and restricted stock units valued at $1,500,000 each on the grant date.
As part of the planned finance leadership transition, Richard J. Buchholz has been appointed interim Chief Financial Officer and designated as interim principal financial officer and interim principal accounting officer through the filing of the 2025 Form 10-K. Inspire also plans investor and analyst meetings in January 2026, supported by an investor presentation made available on its website.
Inspire Medical Systems insider trading report: Chief Product and Innovation Officer John Rondoni reported selling 109 shares of Inspire Medical Systems common stock on January 9, 2026 at a price of
The filing notes that all sale transactions reported were made under a Rule 10b5-1 trading plan dated May 28, 2025, which is a pre-arranged plan intended to allow executives to sell shares over time. The reported holdings include 140 shares acquired through the company’s 2018 Employee Stock Purchase Plan since a prior Form 4 dated May 21, 2025.
An INSP shareholder filed a Rule 144 notice to sell 109 shares of common stock. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC at an aggregate market value of $10,355.00, with the shares listed on the NYSE. The shares were acquired on 06/28/2024 through an employee stock purchase plan from the issuer for cash, and the planned sale date is approximately 01/09/2026. By signing the notice, the seller represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems, Inc. director insider sale reported
Director Shawn T. McCormick reported selling 1,200 shares of Inspire Medical Systems, Inc. common stock on 12/02/2025 at a price of $139 per share. After this transaction, he beneficially owns 24,846 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged plan for trading company stock.
Inspire Medical Systems had an affiliate file a Form 144 notice to potentially sell 1,200 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 12/02/2025. The shares have an aggregate market value of $151,608.00 based on the information provided. Common shares outstanding were 29,056,434 at the time referenced. The seller acquired these 1,200 shares on 03/17/2023 by exercising stock options and paying in cash on that date.
Over the past three months, the same account conducted 10b5-1 sales of 2,000 common shares on 11/28/2025, generating gross proceeds of $254,960.00. The notice includes a representation that the seller does not know of undisclosed material adverse information about the issuer’s current or prospective operations.
Inspire Medical Systems director reports planned stock sale
A director of Inspire Medical Systems reported selling 2,000 shares of common stock on 11/28/2025 at a price of $127.48 per share. After this sale, the director beneficially owns 26,046 shares directly and 3,000 shares indirectly through a trust. The filing notes that all sale transactions were made under a Rule 10b5-1 trading plan dated August 29, 2025, which is a pre-arranged program for trading company stock.
An affiliate of the issuer filed a Form 144 notice to sell 2,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate aggregate market value of $254,660. The filing lists total shares of this class outstanding as 29,056,434.
The shares to be sold were acquired on 03/17/2023 by exercising stock options granted by the issuer, with the purchase price paid in cash on the same date. This notice reflects a planned sale by or for the account of a person related to the issuer under Rule 144, and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
